Clinical trials: Neoadjuvant Treatment
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Breast Neoplasms
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive.
- Trial name
- NCT02510781
- Testing
- Epirubicin, Docetaxel, Trastuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hospital Affiliated to Military Medical Science, Beijing
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
The neoadjuvant Immune Checkpoint Inhibitor (ICI) or ICI combination with chemotherapy for Non-small cell lung cancer (NSCLC) had induced higher major pathologic response (MPR) and complete pathological response (PCR).
- Conditions
- Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, PET/CT
- Trial name
- DYNAPET (NCT04586465)
- Testing
- pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Kidney Cancer
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00849186
- Testing
- sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been…
- Trial name
- NCT03628066
- Testing
- Letrozole, Palbociclib, Goserelin
- Where
- 15 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone plus AC versus Docetaxel plus AC as neoadjuvant chemotherapy in high-risk HER2-negative early-stage or locally advanced breast cancer.
- Trial name
- NCT05673629
- Testing
- Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC
- Where
- China
- Volunteers
- 552 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
This study is designed as an open-label, single-arm, single center, phase II clinical trial, aiming to evaluate the efficacy of neoadjuvant Tislelizumab combined with Nab-Paclitaxel for patients with non-metastatic upper tract…
- Conditions
- Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
- Trial name
- NCT07126119
- Testing
- Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Notable-HCC is a phase Ib study of neoadjuvant stereotactic body radiotherapy (SBRT) plus Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection in patients with resectable HCC.
- Trial name
- Notable-HCC (NCT05185531)
- Testing
- PD-1 plus stereotactic body radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Safety and Efficacy
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4…
- Trial name
- UNLACC (NCT06244537)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Pancreatic Cancer
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline…
- Trial name
- UVA-PC-PD101 (NCT02305186)
- Testing
- Pembrolizumab, Neoadjuvant Chemoradiation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Craig L Slingluff, Jr
Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical…
- Trial name
- NCT00682786
- Testing
- 5FU, Radiation, Surgery of resectable lesions
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Washington University School of Medicine
Retroperitoneal Liposarcoma, Retroperitoneal Leiomyosarcoma
Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
Phase I/II multicenter and prospective trial of nilotinib and adriamycin as neoadjuvant treatment in liposarcomas and leiomyosarcomas of retroperitoneum.
- Conditions
- Retroperitoneal Liposarcoma, Retroperitoneal Leiomyosarcoma, Chondrosarcoma
- Trial name
- GEIS-27 (NCT02587169)
- Testing
- Nilotinib-adriamycin
- Where
- 20 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Broto, Javier Martín, M.D.
Gastric Cancer
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction…
- Trial name
- NCT06374901
- Testing
- Tislelizumab, SOX/XELOX
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Xiangdong Cheng
Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally…
- Trial name
- NCT06354530
- Testing
- anlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Army Medical Center of PLA
Invasive Breast Cancer
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- NCT03381092
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Peking University
Locally Advanced Rectal Cancer
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.
- Trial name
- ENSEMBLE (NCT05646511)
- Testing
- SCRT, CAPOX, CAPOXIRI
- Where
- 34 sites in Japan
- Volunteers
- 608 people
- Sponsor
- National Cancer Center Hospital East
Resectable Stage II-IIIa Squamous NSCLC
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and…
- Trial name
- ECTOP-1036 (NCT07398937)
- Testing
- Serplulimab + chemotherapy, Nivolumab + chemotherapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Fudan University
Rectal Cancer
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
The treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer.
- Trial name
- SOLAR (NCT05673772)
- Testing
- short-course radiotherapy, mFOLFOX6, Chemoradiotherapy
- Where
- 9 sites in South Korea
- Volunteers
- 364 people
- Sponsor
- Kyungpook National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.